Loading clinical trials...
Loading clinical trials...
Perinatal opioid use disorder (OUD) is a major health concern in the U.S. with significant impact on mothers, infants, and communities. Investigators at the University of Kentucky/UK HealthCare (UK) have developed a comprehensive clinical care model for perinatal OUD (known as UK-PATHways) that has demonstrated success in maternal and neonatal outcomes. The overreaching goals of the proposed project are to: 1) expand the reach of this successful clinical program to rural communities thereby improving access to integrated MAT prenatal care, 2) to reduce the impact of perinatal OUD in underserved rural areas of our state, and 3) to compare the relative effectiveness methods of delivery active elements of the UK-PATHways program for rural implementation (local group-support vs. telemedicine).
The UK-PATHways program preliminary successes during the first three years are clear: enrolled mothers (n\>200) have reduced relapse, increased treatment compliance, and improved neonatal outcomes when compared to non-enrolled OUD mothers. However, at this time, UK-PATHways is only available at the main healthcare campus in Lexington, KY. Many eligible patients reside great distances from our clinical home and some current patients travel hours to access this valuable resource. While Medication Assisted Therapy (MAT) has become increasingly available in our region, many of the components of the UK-PATHways program are not readily accessible in rural Central and Eastern Kentucky and the quality of programming with MAT treatment is not standardized in these locations. Furthermore, rural patients continue to face challenges related to stigma of their OUD and transportation difficulties if they desire more comprehensive services. The proposed study will evaluate the introduction of essential components of the UK-PATHways program into rural communities and identify the optimal intervention strategies for expansion of services and to improve the treatment of OUD for rural patients. Specific aims include the following: Aim 1) Conduct a randomized cluster trial using a 'hub and spoke' study design, comparing two delivery modes (local GROUP care vs TELEMEDICINE) for the delivery of a UK-PATHways based patient education curriculum at participating rural regional sites. Each regional site will be randomized to support one of two study arms: 1) Prenatal group care led by a perinatal nurse facilitator or substance use counselor with a peer support specialist (GROUP arm); or, 2) Telemedicine consultation with substance use counselor or perinatal nurse facilitator based at the 'hub' site (TELEMEDICINE arm); and Aim 2) Evaluate the relative effectiveness of each study arm on primary and secondary maternal and neonatal outcomes as compared to the established UK-PATHways program (UK PATHways: Hub) at the University of Kentucky.
Age
18 - 55 years
Sex
FEMALE
Healthy Volunteers
No
Karen's Place Maternity Center
Ashland, Kentucky, United States
The Medical Center
Bowling Green, Kentucky, United States
Grace Health Women's Care
Corbin, Kentucky, United States
BrightView
Georgetown, Kentucky, United States
University of Kentucky Women's Health OB-GYN
Georgetown, Kentucky, United States
Primary Care Centers of Eastern Kentucky
Hazard, Kentucky, United States
OB/GYN & Women's Health University of Louisville
Louisville, Kentucky, United States
ARH Women's and Family Health Center - Middlesboro
Middlesboro, Kentucky, United States
University of Kentucky Morehead Women's Healthcare
Morehead, Kentucky, United States
Frontier Behavioral Health Centers
Prestonsburg, Kentucky, United States
Start Date
March 13, 2019
Primary Completion Date
April 1, 2024
Completion Date
November 1, 2024
Last Updated
May 1, 2025
269
ACTUAL participants
Telemedicine
BEHAVIORAL
Group Care
BEHAVIORAL
Lead Sponsor
Wendy F Hansen
NCT04783558
NCT05129020
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions